PE20071143A1 - Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 - Google Patents
Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6Info
- Publication number
- PE20071143A1 PE20071143A1 PE2006001716A PE2006001716A PE20071143A1 PE 20071143 A1 PE20071143 A1 PE 20071143A1 PE 2006001716 A PE2006001716 A PE 2006001716A PE 2006001716 A PE2006001716 A PE 2006001716A PE 20071143 A1 PE20071143 A1 PE 20071143A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxitriptamine
- antagonist
- pharmaceutical composition
- composition including
- acetylcholinesterase inhibitor
- Prior art date
Links
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 229960003980 galantamine Drugs 0.000 abstract 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960004136 rivastigmine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A)UN INHIBIDOR DE ACETILCOLINESTERASA SELECCIONADO DE DONEPEZIL, GALANTAMINA Y RIVASTIGMINA; Y B) UN ANTAGONISTA 5-HIDROXITRIPTAMINA-6 DE FORMULA (I), EN DONDE R1 ES -W(CR5R6)nNR7R8, a), ENTRE OTROS, DONDE W ES O, S, NR, ENTRE OTROS; R2 ES H, HALOGENO, CN, OR12, CO2R17, ENTRE OTROS; R3 ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS; R4 ES ARILO, HETEROARILO O UN ANILLO BI O TRICICLICO DE 8 A 13 MIEMBROS, SIENDO SELECCIONADOS: 3-(1-NAFTILSULFONIL)-5-PIPERAZIN-1-IL-1H-INDAZOL, 1,1-DIMETIL-3-{[3-(1-NAFTILSULFONIL)-1H-INDAZOL-5-IL]OXI}PROPAN-1-AMINA, ENTRE OTROS. DICHA COMPOSICION PUEDE ADMINISTRARSE EN FORMA SIMULTANEA, SEPARADA O SECUENCIAL, SIENDO UTIL EN EL TRATAMIENTO DE TRASTORNO COGNOCITIVO, TAL COMO LA ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75884106P | 2006-01-13 | 2006-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20071143A1 true PE20071143A1 (es) | 2008-01-20 |
Family
ID=38109582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006001716A PE20071143A1 (es) | 2006-01-13 | 2006-12-28 | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20070167431A1 (es) |
| EP (1) | EP1971334A2 (es) |
| JP (1) | JP2009523728A (es) |
| KR (1) | KR20080096657A (es) |
| CN (1) | CN101370499A (es) |
| AR (1) | AR060019A1 (es) |
| AU (1) | AU2007208516A1 (es) |
| BR (1) | BRPI0706515A2 (es) |
| CA (1) | CA2635920A1 (es) |
| CR (1) | CR10139A (es) |
| EC (1) | ECSP088619A (es) |
| GT (1) | GT200800138A (es) |
| IL (1) | IL192694A0 (es) |
| MX (1) | MX2008009021A (es) |
| NO (1) | NO20082894L (es) |
| PE (1) | PE20071143A1 (es) |
| RU (1) | RU2008126245A (es) |
| TW (1) | TW200733976A (es) |
| WO (1) | WO2007087151A2 (es) |
| ZA (1) | ZA200806070B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06000795A (es) | 2003-07-22 | 2006-08-23 | Arena Pharm Inc | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5-ht2a de serotonina utiles para la profilaxis y tratamiento de desordenes relacionados con el mismo. |
| CN101500611A (zh) * | 2006-06-23 | 2009-08-05 | 埃斯蒂维实验室股份有限公司 | 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合 |
| AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
| US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
| WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
| RU2467749C1 (ru) * | 2011-04-21 | 2012-11-27 | Государственное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения и социального развития Российской Федерации | Способ коррекции уровня сахара крови и лечения пациентов с сахарным диабетом второго типа с когнитивными нарушениями |
| JO3459B1 (ar) * | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| MX390081B (es) * | 2014-11-03 | 2025-03-20 | Iomet Pharma Ltd | Compuesto farmacéutico. |
| CA2985370A1 (en) * | 2015-05-07 | 2016-11-10 | Axovant Sciences Gmbh | Compositions and methods of treating a neurodegenerative disease |
| MX388281B (es) | 2015-06-12 | 2025-03-11 | Axovant Sciences Gmbh | Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamiento de un trastorno conductual del sueño rem. |
| HK1247555A1 (zh) | 2015-07-15 | 2018-09-28 | Axovant Sciences Gmbh | 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物 |
| WO2017147601A1 (en) * | 2016-02-25 | 2017-08-31 | Axovant Sciences Gmbh | Methods of improving balance, gait or both in patients with neurological disease |
| CA3020557C (en) * | 2016-04-26 | 2024-05-21 | H. Lundbeck A/S | Use of an acetylcholinesterase inhibitor and idalopirdine for reducing falls in parkinson's disease patients |
| US10864191B2 (en) * | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
| NZ748280A (en) * | 2016-05-18 | 2020-07-31 | Suven Life Sciences Ltd | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL213134B1 (pl) * | 2000-11-02 | 2013-01-31 | Wyeth Corp | 1-arylo- lub 1-alkilosulfonylo- heterocyklilobenzazole, ich zastosowanie oraz kompozycja farmaceutyczna zawierajaca te zwiazki |
| PL377777A1 (pl) * | 2002-12-11 | 2006-02-20 | Pharmacia & Upjohn Company Llc | Leczenie chorób połączeniami agonistów receptora alfa 7-nikotynowego i innych związków |
| CN100422171C (zh) * | 2003-02-14 | 2008-10-01 | 惠氏公司 | 作为5-羟色胺-6配体的杂环-3-磺酰基吲唑 |
| JP5146766B2 (ja) * | 2005-08-15 | 2013-02-20 | ワイス・エルエルシー | ５−ヒドロキシトリプタミン−６リガンドとしての置換−３−スルホニルインダゾール誘導体 |
-
2006
- 2006-12-28 PE PE2006001716A patent/PE20071143A1/es not_active Application Discontinuation
-
2007
- 2007-01-05 TW TW096100409A patent/TW200733976A/zh unknown
- 2007-01-09 JP JP2008550355A patent/JP2009523728A/ja not_active Withdrawn
- 2007-01-09 CA CA002635920A patent/CA2635920A1/en not_active Abandoned
- 2007-01-09 RU RU2008126245/14A patent/RU2008126245A/ru not_active Application Discontinuation
- 2007-01-09 CN CNA200780003019XA patent/CN101370499A/zh active Pending
- 2007-01-09 KR KR1020087019279A patent/KR20080096657A/ko not_active Withdrawn
- 2007-01-09 EP EP07716405A patent/EP1971334A2/en not_active Withdrawn
- 2007-01-09 BR BRPI0706515-9A patent/BRPI0706515A2/pt not_active IP Right Cessation
- 2007-01-09 MX MX2008009021A patent/MX2008009021A/es not_active Application Discontinuation
- 2007-01-09 AU AU2007208516A patent/AU2007208516A1/en not_active Abandoned
- 2007-01-09 WO PCT/US2007/000354 patent/WO2007087151A2/en not_active Ceased
- 2007-01-12 US US11/652,725 patent/US20070167431A1/en not_active Abandoned
- 2007-01-12 AR ARP070100160A patent/AR060019A1/es unknown
-
2008
- 2008-06-30 NO NO20082894A patent/NO20082894L/no not_active Application Discontinuation
- 2008-07-08 IL IL192694A patent/IL192694A0/en unknown
- 2008-07-10 GT GT200800138A patent/GT200800138A/es unknown
- 2008-07-11 EC EC2008008619A patent/ECSP088619A/es unknown
- 2008-07-11 ZA ZA200806070A patent/ZA200806070B/xx unknown
- 2008-07-11 CR CR10139A patent/CR10139A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007087151A3 (en) | 2007-11-15 |
| JP2009523728A (ja) | 2009-06-25 |
| CN101370499A (zh) | 2009-02-18 |
| BRPI0706515A2 (pt) | 2011-03-29 |
| EP1971334A2 (en) | 2008-09-24 |
| ZA200806070B (en) | 2009-04-29 |
| AU2007208516A1 (en) | 2007-08-02 |
| CR10139A (es) | 2008-09-30 |
| NO20082894L (no) | 2008-09-30 |
| ECSP088619A (es) | 2008-08-29 |
| GT200800138A (es) | 2008-10-06 |
| AR060019A1 (es) | 2008-05-21 |
| IL192694A0 (en) | 2009-02-11 |
| RU2008126245A (ru) | 2010-02-20 |
| AU2007208516A8 (en) | 2008-08-07 |
| CA2635920A1 (en) | 2007-08-02 |
| MX2008009021A (es) | 2008-09-24 |
| US20070167431A1 (en) | 2007-07-19 |
| TW200733976A (en) | 2007-09-16 |
| WO2007087151A2 (en) | 2007-08-02 |
| KR20080096657A (ko) | 2008-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20071143A1 (es) | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 | |
| PE20091734A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| ATE537830T1 (de) | Nicotinamid derivate und ihre verwendung als therapeutika | |
| UY32391A (es) | Compuestos amino-heterocíclicos | |
| PE20080714A1 (es) | DERIVADOS HETEROCICLICOS COMO MODULADORES DE LA ACTIVIDAD DE LA ESTEARIL-CoA-DESATURASA | |
| PE20121182A1 (es) | Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina | |
| PE20060531A1 (es) | Derivados de piridazin-3-(2h)-ona como inhibidores de la fosfodiesterasa 4 | |
| PE20090902A1 (es) | Combinacion de un antimitotico e inhibidor de aurora quinasa como agentes anticancerigenos | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| UY29963A1 (es) | Compuestos terapéuticos: piridinas y pirazinas como andamios | |
| MY153941A (en) | Compounds as bradykinin b1 antagonists | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| ATE425166T1 (de) | Amidderivate von 3-phenyldihydropyrimidoä4,5- düpyrimidinonen, deren herstellung und verwendung als pharmazeutische mittel | |
| ECSP088863A (es) | Compuestos que son agonistas de receptores muscarínicos y que pueden ser eficaces en el tratamiento del dolor, la enfermedad de alzheimer y/o la esquizofrenia | |
| MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
| DE602005023015D1 (de) | Indolderivate als viruzide | |
| UY28736A1 (es) | Derivados de quinazolina | |
| PE20140703A1 (es) | Derivados de heteroarilo como moduladores de nachr alfa 7 | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| PE20121556A1 (es) | 3,6-diazabiciclo[3.1.1]heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina | |
| DE602004018630D1 (en) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| PE20071177A1 (es) | Derivados de 3,5-piridina como inhibidores de renina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |